Published in Transpl Int on December 01, 2006
Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol (2015) 0.83
Metabolic syndrome after liver transplantation: preventable illness or common consequence? World J Gastroenterol (2012) 0.79
Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol (2016) 0.75
Hepatobiliary Quiz Answers-17 (2016). J Clin Exp Hepatol (2016) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2009) 5.26
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol (2013) 2.71
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol (2002) 2.65
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. Neuropsychology (2009) 2.29
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int (2011) 2.25
Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol (2004) 2.15
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol (2007) 2.14
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Factor structure of the brief symptom inventory--18 in adult survivors of childhood cancer: results from the childhood cancer survivor study. Psychol Assess (2006) 2.08
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. Surg Endosc (2012) 2.04
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Progenitor cells in diseased human liver. Semin Liver Dis (2003) 1.93
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol (2003) 1.80
Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol (2007) 1.68
Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol (2002) 1.66
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes (2004) 1.62
Peer-delivered smoking counseling for childhood cancer survivors increases rate of cessation: the partnership for health study. J Clin Oncol (2005) 1.61
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol (2010) 1.61
The histology of kidney transplant failure: a long-term follow-up study. Transplantation (2014) 1.61
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology (2005) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients. Clin Cancer Res (2014) 1.55
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways. Transpl Int (2011) 1.53
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology (2011) 1.43
Lipid peroxidation products in machine perfusion of older donor kidneys. J Surg Res (2012) 1.42
Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol (2012) 1.42
Smoking among participants in the childhood cancer survivors cohort: the Partnership for Health Study. J Clin Oncol (2003) 1.42
The extent of vacuolation in non-heart-beating porcine donor liver grafts prior to transplantation predicts their viability. Liver Transpl (2008) 1.41
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin (2010) 1.40
GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.40
Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation (2009) 1.38
Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32
Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection? Transfusion (2007) 1.31
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2012) 1.26
Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg (2003) 1.25
Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.24